Skip to main content Accessibility help

Fecal Microbiota Therapy: Ready for Prime Time?

  • Krishna Rao (a1), Vincent B. Young (a1) (a2) and David M. Aronoff (a3) (a4)


  • An abstract is not available for this content so a preview has been provided below. Please use the Get access link above for information on how to access this content.


Corresponding author

3120 Taubman Center, 1500 East Medical Center Drive, SPC 5378, Ann Arbor, MI 48109 (


Hide All
1. Hurley, BW, Nguyen, CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002;162(19):21772184.
2. Yatsunenko, T, Rey, FE, Manary, MJ, et al. Human gut micro-biome viewed across age and geography. Nature 2012;486(7402): 222227.
3. Figueroa, I, Johnson, S, Sambol, SP, Goldstein, EJC, Citron, DM, Gerding, DN. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012;55(suppl 2):S104S109.
4. McFarland, LV, Elmer, GW, Surawicz, CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002;97(7):17691775.
5. Garey, KW, Ghantoji, SS, Shah, DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rif-aximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011;66(12): 28502855.
6. Johnson, S, Gerding, DN. Fidaxomicin “chaser” regimen following vancomycin for patients with multiple C. difficile recurrences. Clin Infect Dis 2012;309310.
7. Gough, E, Shaikh, H, Manges, AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53(10):9941002.
8. van Nood, E, Vrieze, A, Nieuwdorp, M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile . N Engl J Med 2013;368(5):407415.
9. Lofgren, ET, Moehring, RW, Anderson, DJ, Weber, DJ, Fefferman, NH. A mathematical model to evaluate the routine use of fecal microbiota transplantation to prevent incident and recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 2013;35:1827 (in this issue).
10. Chang, JY, Antonopoulos, DA, Kalra, A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008;197(3):435438.
11. Young, VB, Schmidt, TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004;42(3): 12031206.
12. Warny, M, Pepin, J, Fang, A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366(9491):10791084.
13. Rao, K, Micie, D, Chenoweth, E, et al. Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc 2013;61(10):17381742.
14. Barbut, F, Petit, JC. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001;7(8):405410.
15. Welfare, MR, Lalayiannis, LC, Martin, KE, Corbett, S, Marshall, B, Sarma, JB. Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 2011;79(4):359363.
16. Besselink, MGH, van Santvoort, HC, Buskens, E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371(9613):651659.
17. De Leon, LM, Watson, JB, Kelly, CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013;11(8): 10361038.
18. Sekirov, I, Russell, SL, Antunes, LCM, Finlay, BB. Gut microbiota in health and disease. Physiol Rev 2010;90(3):859904.
19. Garrett, WS, Lord, GM, Punit, S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007;131(1):3345.

Fecal Microbiota Therapy: Ready for Prime Time?

  • Krishna Rao (a1), Vincent B. Young (a1) (a2) and David M. Aronoff (a3) (a4)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed